Fennec Pharmaceuticals Ord Shs T.FRX

Alternate Symbol(s): FENC

Healthcare Biotechnology

Fennec Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company focused on its product candidate PEDMARK. It sells its product through a field force, including Regional Pediatric Oncology Specialists and medical science liaisons who are helping to educate the medical communities and patients about cisplatin induced ototoxicity and its programs supporting patient access to PEDMARK. PEDMARK is a Food and Drug Administration approved therapy indicated to reduce the risk of ototoxicity associated with cisplatin treatment in pediatric patients with localized, non-metastatic, solid tumors. It is a formulation of sodium thiosulfate in single-dose, ready-to-use vials for intravenous use in pediatric patients. PEDMARK is a therapeutic agent with a dosing paradigm, across two open-label, randomized Phase 3 clinical studies, the Clinical Oncology Group (COG) Protocol ACCL0431 and SIOPEL 6. It has established Fennec HEARS, a single source program designed to connect PEDMARK patients.

TSX:FRX - Post by User

Fennec Pharmaceuticals Ord Shs

Bullboard Posts

Post by dollarhunteron Feb 21, 2007 4:03pm

329 Views

Post# 12282183

Don't forget us shareholders!

Thought most here would like to learn more about the company that holds the majority of Adherex as of today. bullboards/wraplink.asp?url=www.southpoint1.com/index.html''> https://www.southpoint1.com/index.html The big question now is wether they take Adherex private leaving us with a slight profit instead of the big gains that are inevitable in the future or if they just help the company's timeline along and take us with them. I'm hoping for the latter as $25.00/share is quite posible with clinical success now that financing is no longer a problem. Regards, DH

Bullboard Posts

Changing Europe’s dependency on HREE from China